[Experience with velcade administration in multiple myeloma].
OBJECTIVE
To study efficacy of velcade therapy for progressive or resistant multiple myeloma (MM).


METHODS
We used velcade in therapy of 36 patients (18 males and 18 females, age 43-76, age median 58 years) with progressive or resistant MM from April 2006 to February 2008. Prior second line standard therapy failed. A total of 206 courses of treatment were performed.


RESULTS
Treatment outcomes were assessed in 34 patients, 2 patients continue treatment. Overall response was 55.9% (EBMT criterion). A complete, partial and minimal responses were achieved in 10, 4 and 5 cases, respectively. No response was observed in 11 patients. Velcade was administered in polyresistance to polychemotherapy (PCT) programs including VAD (5 patients), contraindications for PCT because of old age or comorbid pathology (13 patients). These patients received 1-9 courses of velcade (as monotherapy in 28 patients, in combination with high-dose dexamethasone in 6 patients, in combination with high-dose dexamethasone and doxorubicin in 3 patients with progressive disease). Follow-up of this group from the start of velcade therapy was 4-15 months. Velcade induced stabilization of the disease in 4 patients (follow-up median was 8 months), progression of the disease in 5-9 months occurred in 6 patients.
Kaporskaia
T S
TS
Kiselev
I V
IV
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib